ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 22 Issue : 5
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(6): 523-529 | DOI: 10.5152/akd.2011.137  

Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure

Serhat Işık1, Mustafa Çetin2, Hülya Çiçekcioğlu3, Özgül Uçar4, Zehra Güven Çetin3, Ufuk Özuğuz5, Fatih Bakır6, Dilek Berker1, Serdar Güler1
1Ankara Numune Research and Training Hospital, Endocrinology and Metabolism Clinic, Ankara, Turkey
2Clinic of Cardiology, Rize Education and Research Hospital, Rize-Turkey
3Clinic of 2nd Cardiology Ankara Numune Research and Training Hospital, Ankara-Turkey
4Ankara Numune Hastanesi, 1. Kardiyoloji Kliniği Ankara, Türkiye
5Clinic of Endocrinology and Metabolism, Ankara Numune Research and Training Hospital, Ankara-Turkey
6Department of Biochemistry, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara-Turkey

Objective: Levosimendan treatment has inotropic, anti-stunning, and cardioprotective effects in the setting of acute decompensated heart failure (HF). Among studies conducted on the treatment of heart failure, those based on the growth hormone axis are of particular interest. The aim of this study was to determine the value of baseline insulin-like growth factor 1 (IGF-I) measurements in predicting response to levosimendan treatment. Methods: The study population included patients on standard heart failure treatment who presented with functional capacity NYHA class 3-4 and left ventricular (LV) ejection fraction less than 35% were enrolled in this prospective, cohort study. Pre- and post-treatment symptoms of patients (72 hours after the completion of levosimendan infusion) and echocardiographic parameters were evaluated and blood samples were collected. Mann-Whitney U, Pearson Chi-square and Wilcoxon Sign Rank tests were used for statistical analysis. Correlations were determined using Spearman correlation analysis. Results: Thirty patients were enrolled in this study, 83.3% of whom were male and 16.7% were female, with a mean age of 62.6 ±10.1 years. Mean baseline IGF-I level was 106.9±47.0 µg/L. Statistically significant improvements were observed in NYHA class, mean brain natriuretic peptide (BNP) levels, LV ejection fraction and LV end-systolic volume values following treatment with levosimendan (respective pre-treatment and post-treatment values: 3.5±0.5 vs. 2.5±0.7, p<0.001; 1209.8±398.6 pg/ml vs. 704.1±344.6 pg/ml, p<0.001, and 25.7±6.6% vs. 29.0±6.8%, p=0.021, and 164.1±45.7 ml vs. 152.8±50.6 ml, p=0.012). Fourteen patients (46.7%) had low IGF-I levels, taking into consideration variations due to age and gender. Patients with normal baseline IGF-I values showed more significant decreases in BNP levels in response to treatment compared to those with low baseline IGF-I levels (650.5±367.2 pg/ml vs. 340.1±269.0 pg/ml, p=0.014). Conclusion: Baseline IGF-I levels may be used to predict response to levosimendan treatment in patients hospitalized for decompensated HF.

Keywords: Heart failure, levosimendan, insulin-like growth factor 1, B type natriuretic peptide


Serhat Işık, Mustafa Çetin, Hülya Çiçekcioğlu, Özgül Uçar, Zehra Güven Çetin, Ufuk Özuğuz, Fatih Bakır, Dilek Berker, Serdar Güler. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure. Anatol J Cardiol. 2011; 11(6): 523-529


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology